Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Ulrich Germing, Katharina Götze, Philipp Kiewe, MD, Thomas Wolff, MD, Karin Mayer, MD, Joerg Chromik, MD, Markus Radsak, MD, Eileen Donovan, Dawn M. Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD, Aristoteles Giagounidis

Blood (2016) 128 (22): 3168.

https://doi.org/10.1182/blood.V128.22.3168.3168

Published: 2016

Journal Articles

Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)

Uwe Platzbecker, Ulrich Germing, Katharina Götze, Philipp Kiewe, MD, Thomas Wolff, MD, Karin Mayer, MD, Joerg Chromik, MD, Markus Radsak, MD, Eileen Donovan, Dawn M. Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD, Aristoteles Giagounidis

Blood (2016) 128 (22): 5551.

https://doi.org/10.1182/blood.V128.22.5551.5551

Published: 2016

Journal Articles

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

Uwe Platzbecker, MD, Ulrich Germing, MD, Aristoteles Giagounidis, MD PhD, Katharina Götze, MD, Philipp Kiewe, MD, Karin Tina Mayer, MD, Oliver Ottmann, MD, Markus Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Abderrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 2862.

https://doi.org/10.1182/blood.V126.23.2862.2862

Published: 2015

Journal Articles

Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study

Aristoteles Giagounidis, MD PhD, Uwe Platzbecker, MD, Ulrich Germing, MD, Katharina Götze, MD, Philipp Kiewe, MD, Karin Tina Mayer, MD, Oliver Ottmann, MD, Markus Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn Wilson, Xiaosha Zhang, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2015) 126 (23): 92.

https://doi.org/10.1182/blood.V126.23.92.92

Published: 2015

Journal Articles

ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study

Uwe Platzbecker, MD, Ulrich Germing, MD, Aristoteles Giagounidis, MD PhD, Katharina Goetze, MD, Philipp Kiewe, MD, Karin Mayer, MD, Oliver Ottman, MD, Markus P. Radsak, MD, Thomas Wolff, MD, Detlef Haase, MD, Monty Hankin, Dawn M. Wilson, Adberrahmane Laadem, MD, Matthew L. Sherman, MD, Kenneth M. Attie, MD

Blood (2014) 124 (21): 411.

https://doi.org/10.1182/blood.V124.21.411.411

Published: 2014

Journal Articles

Activity Of Single Agent Temsirolimus and Associated Impact On Bone Marrow Vascularization and T-Cell Composition In Patients With Myelodysplastic Syndromes – Result Of The Prospective Temds Trial Of The German MDS-SG

Martin Wermke, MD, Claudia Schuster, Claudia Schönefeldt, Christiane Jakob, MD, Malte von Bonin, MD, Florian Nolte, MD, Philipp Kiewe, MD, Regina Herbst, MD, Ulrich Germing, MD, Michael Aigner, PhD, Detlef Haase, MD, Ina-Maria Klut, PhD, Nadja Jaekel, Gustavo Baretton, MD, Martin Bornhäuser, MD, Gerhard Ehninger, MD, Wolf-Karsten Hofmann, MD, Uwe Platzbecker, MD, PhD

Blood (2013) 122 (21): 2808.

https://doi.org/10.1182/blood.V122.21.2808.2808

Published: 2013

Journal Articles

Primary Central Nervous System Lymphoma (PCNSL): Intent-to-Treat Analysis of Monocenter Long-Term Experience.

Agnieszka Korfel, MD, Philipp Kiewe, MD, Lars Fischer, MD, Peter Mertus, PhD, Eckhard Thiel, PhD

Blood (2007) 110 (11): 1365.

https://doi.org/10.1182/blood.V110.11.1365.1365

Published: 2007

Journal Articles

CXCL12 and CXCL13 Levels in Cerebrospinal Fluid (CSF) of Patients with CNS Lymphoma.

Lars Fischer, MD, Philipp Kiewe, MD, Sebastian Pfeiffer, MD, Hüsniye Cakiroglu, Eckhard Thiel, MD

Blood (2007) 110 (11): 1576.

https://doi.org/10.1182/blood.V110.11.1576.1576

Published: 2007

Journal Articles

Penetration of Yttrium-90-Labeled Ibritumomab Tiuxetan (Zevalin™) into Primary CNS Lymphoma.

Philipp Kiewe, MD, Agnieszka Korfel, MD, Sofiane Maza, MD, Kristoph Jahnke, MD, Dieter L. Munz, MD, Eckhard Thiel, MD

Blood (2006) 108 (11): 2724.

https://doi.org/10.1182/blood.V108.11.2724.2724

Published: 2006

NARROW

Luspatercept Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS): Long-Term Results from Phase 2 PACE-MDS Study

Luspatercept Response in ESA-NaïVe/RS+ Patients and RS- Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)

Biomarkers of Ineffective Erythropoiesis Predict Response to Luspatercept in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Final Results from the Phase 2 PACE-MDS Study

Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study

ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study

Activity Of Single Agent Temsirolimus and Associated Impact On Bone Marrow Vascularization and T-Cell Composition In Patients With Myelodysplastic Syndromes – Result Of The Prospective Temds Trial Of The German MDS-SG

Primary Central Nervous System Lymphoma (PCNSL): Intent-to-Treat Analysis of Monocenter Long-Term Experience.

CXCL12 and CXCL13 Levels in Cerebrospinal Fluid (CSF) of Patients with CNS Lymphoma.

Penetration of Yttrium-90-Labeled Ibritumomab Tiuxetan (Zevalin™) into Primary CNS Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only